BioBridgeX
Log inCompare quotes
Modality

Antibody Fragment / Fusion Protein CRO and CDMO vendors

Free for buyersNeutral vendor of record
Quick answer

Outsourcing an antibody fragment or Fc-fusion protein means hiring CRO and CDMO partners to engineer the construct, build a stable cell line, run microbial or mammalian fermentation, and purify a correctly folded molecule with controlled aggregation. It needs half-life-extension strategy, potency and binding assays, host-cell-protein clearance, and GMP fill-finish. BioBridgeX is a neutral vendor of record: free for buyers, one contract across vendors.

Antibody Fragment / Fusion Protein CRO and CDMO vendors on BioBridgeX

We are qualifying and publishing Antibody Fragment / Fusion Protein CRO and CDMO vendors now. Tell us what you need and we will match you with vetted vendors, or list your organization to be among the first.

What does it take to develop and manufacture an Antibody Fragment / Fusion Protein drug?

This modality is a broad family that behaves very differently depending on what you are building. A Fab, scFv, or VHH (single-domain antibody, the nanobody class) is a small engineered binder, often aglycosylated, that you can usually express in E. coli or another microbial host. An Fc-fusion protein, the etanercept and abatacept style of molecule, fuses a receptor domain or peptide to an antibody Fc, needs proper glycosylation for its half-life and effector behavior, and therefore lives in CHO or another mammalian system. The first scoping question with any vendor is which of these you actually have, because the cell line, the expression host, and the whole CMC plan branch from that single answer.

On the discovery and early side, the work is construct engineering and developability. Fragments lose the long serum half-life that a full IgG gets from FcRn recycling, so half-life extension is usually designed in from the start: PEGylation, albumin binding (an anti-albumin VHH or an albumin-binding domain), or fusing to an Fc. Each route changes the downstream analytics and the manufacturing footprint, so it is a decision to make with your CDMO in the room, not after the cell line is locked. Developability screening here is real work, not a checkbox: scFvs are prone to aggregation and to forming diabodies, microbial expression of fragments often lands in inclusion bodies that need a refold, and a construct that titers beautifully but aggregates on storage will haunt you at formulation.

Manufacturing is where a specialist CDMO earns its fee over a generalist. Microbial fragment processes turn on inclusion-body recovery and refolding yield, endotoxin clearance, and removing host-cell protein and DNA from an E. coli background, which is a different problem set than a clean CHO supernatant. Fc-fusion processes turn on glycan control, aggregate and clipped-species removal, and Protein A capture that has to tolerate the fusion partner. Across both, the analytical package is the heart of the program: identity and sequence confirmation, a potency or binding assay (SPR or BLI for affinity, plus a cell-based functional readout where the mechanism demands it), aggregate and charge-variant profiling by SEC and icIEF, host-cell-protein and residual-DNA ELISAs, and endotoxin. A generalist mammalian CDMO can often run an Fc-fusion competently; a microbial fragment with a refold step and a PEGylation conjugation is where you want a shop that has actually shipped one, because the failure modes are specific and expensive to learn on your own program.

How do you choose a CRO or CDMO for Antibody Fragment / Fusion Protein?

Match the vendor to your exact construct and expression host first, then work through capability, capacity, regulatory record, and IP. The checklist below is what experienced sourcing teams actually press on when they compare two or three shortlisted vendors against the same written scope.

  • Relevant platform and track record: confirm they have run your specific format, a microbial Fab/scFv/VHH with a refold and the right expression host, or a mammalian Fc-fusion in CHO, not just full IgGs. Ask for redacted case studies, titers achieved, and whether any program reached GMP and the clinic.
  • Half-life-extension and conjugation experience: if your molecule is PEGylated, albumin-binding, or Fc-fused, the vendor needs hands-on experience with that route, including the conjugation chemistry and the analytics to characterize the modified product.
  • GxP and analytical capability for this modality: developability and assay development can sit with a research-grade CRO, but IND-enabling tox material and clinical supply need GMP. Check the analytical method list maps to this molecule (SEC, icIEF or cIEF, SPR/BLI, peptide mapping, intact and reduced mass, host-cell-protein and residual-DNA ELISAs, endotoxin, and a qualified potency assay), and that they can develop and validate those methods, not just run yours.
  • Capacity and scale: confirm fermentation or bioreactor scale fits your phase, with a credible path from grams for tox to the kilogram quantities a Phase 3 or commercial Fc-fusion needs, plus formulation and fill-finish either in house or through a named partner so you are not stranded after drug substance.
  • Regulatory experience: ask whether they have authored CMC sections that cleared an IND or a BLA for a biologic, and whether they work fluently with ICH Q5C, Q5E, Q6B, and the comparability expectations that bite when you change scale or site mid-program.
  • IP and confidentiality: pin down ownership of cell line, process, and analytical methods in writing, watch for platform fees or reach-through on a proprietary expression or half-life-extension technology, and get a CDA in place before you disclose sequence.

Frequently asked questions

What is the difference between an antibody fragment and a full monoclonal antibody for CMC purposes?
A full mAb is a large glycosylated IgG that almost always runs in CHO, gets its long half-life from FcRn recycling, and has a well-trodden Protein A capture platform. Antibody fragments (Fab, scFv, VHH) are smaller, often aglycosylated, and can be made in microbial hosts like E. coli, which is cheaper and faster but introduces inclusion-body recovery, refolding, and endotoxin and host-cell-protein clearance from a bacterial background. Fragments also lose Fc-driven half-life, so a half-life-extension strategy (PEGylation, albumin binding, or Fc fusion) is usually part of the design. The upshot is that the expression host, the purification problem, and the analytical package all differ, so a CDMO strong on mAbs is not automatically the right fit for a microbial fragment.
Should my antibody fragment be made in E. coli or a mammalian system?
It depends on the molecule. Aglycosylated fragments (Fabs, scFvs, VHHs) are frequently expressed in E. coli, which gives high cell density, lower cost, and fast timelines, at the price of dealing with inclusion bodies and refolding for some constructs and tighter endotoxin and host-cell-protein control. Anything that needs glycosylation, notably an Fc-fusion protein where the Fc glycan drives half-life and effector function, goes into CHO or another mammalian host. Some fragments are also expressed in yeast (Pichia). The right answer falls out of the construct, so settle it with a CDMO that runs both before you commit to a host.
How is half-life extension handled for antibody fragments?
Because fragments lack the IgG Fc that gives full antibodies their multi-week serum half-life, developers usually engineer half-life back in. The common routes are PEGylation (attaching polyethylene glycol to slow renal clearance), albumin binding (an anti-albumin VHH, an albumin-binding domain, or direct albumin fusion that hitchhikes on albumin's FcRn recycling), and Fc fusion (which also recovers FcRn recycling and can restore effector function). Each route changes manufacturing and analytics: PEGylation adds a conjugation step and PEG-specific characterization, albumin binding adds a binding partner to the potency story, and Fc fusion pushes you into mammalian expression. Decide this early, since it shapes the entire CMC plan.
What analytical methods does a fragment or Fc-fusion program need?
Plan for identity and sequence confirmation (peptide mapping, intact and reduced mass), a binding assay by SPR or BLI plus a cell-based potency assay where the mechanism requires one, aggregate and fragment profiling by SEC, charge-variant analysis by icIEF or cIEF, and for glycosylated Fc-fusions a glycan profile. Process-related impurity tests include host-cell-protein and residual-DNA ELISAs (with extra attention to endotoxin and host-cell protein for a microbial process) and any conjugation-specific assays for a PEGylated or albumin-bound product. A CDMO should be able to develop and qualify these methods for your specific molecule, not only run methods you hand over.
What regulatory framework applies to these molecules in the US?
Antibody fragments and Fc-fusion proteins are biologics, so the US path runs through an IND for clinical trials and a BLA for approval, not the NDA route used for small molecules. The relevant ICH guidance includes Q5C (stability), Q5E (comparability after a manufacturing change), Q6B (specifications for biotech products), and Q2 for analytical validation. Comparability matters more than first-timers expect: scaling up, changing a site, or moving from a tox lot to clinical supply can trigger a comparability exercise to show the product is unchanged. A CDMO that has authored CMC sections through an IND and ideally a BLA for a biologic will save real time here.
How does BioBridgeX work for buyers sourcing this modality, and what does it cost?
BioBridgeX is a neutral vendor of record. You can self-serve to scope your project and compare qualified CROs and CDMOs that actually work on antibody fragments and Fc-fusion proteins, matched on platform, expression host, GxP status, and capacity rather than on who markets hardest. It is free for buyers. When you engage one or several vendors, you sign one contract and receive one PO and one invoice across them, with a flat 2% fee charged to the vendor, not to you. Because BioBridgeX does not own the labs, the recommendation stays neutral. The same model spans all indications and modalities, so a multi-part program can sit under a single agreement.

Source Antibody Fragment / Fusion Protein work with one contract

Compare transparent quotes from qualified Antibody Fragment / Fusion Protein CRO and CDMO vendors, then contract once. Free for buyers.

Compare quotes